Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
ep us feature image
February 4, 2026 1:02 PM 4 min read

Earnings Outlook For Exponent

by Benzinga Insights Benzinga Staff Writer
Follow

ArticleFeaturedTickersList12345!!!

Exponent (NASDAQ:EXPO) is gearing up to announce its quarterly earnings on Thursday, 2026-02-05. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Exponent will report an earnings per share (EPS) of $0.47.

The announcement from Exponent is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.

It's worth noting for new investors that guidance can be a key determinant of stock price movements.

Performance in Previous Earnings

Last quarter the company beat EPS by $0.03, which was followed by a 5.97% increase in the share price the next day.

Here's a look at Exponent's past performance and the resulting price change:

Quarter Q3 2025 Q2 2025 Q1 2025 Q4 2024
EPS Estimate 0.52 0.50 0.52 0.43
EPS Actual 0.55 0.52 0.52 0.46
Price Change % 6.00 -1.00 -1.00 1.00

Performance of Exponent Shares

Shares of Exponent were trading at $69.92 as of February 03. Over the last 52-week period, shares are down 21.53%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release.

Analysts' Perspectives on Exponent

For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Exponent.

The consensus rating for Exponent is Neutral, derived from 2 analyst ratings. An average one-year price target of $90.5 implies a potential 29.43% upside.

Peer Ratings Overview

The analysis below examines the analyst ratings and average 1-year price targets of Science Applications Intl, Andersen Group and CBIZ, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.

Comprehensive Peer Analysis Summary

The peer analysis summary offers a detailed examination of key metrics for Science Applications Intl, Andersen Group and CBIZ, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

Key Takeaway:

Exponent ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. Exponent is at the bottom for Return on Equity.

Unveiling the Story Behind Exponent

Exponent's Economic Impact: An Analysis

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Net Margin: Exponent's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 19.06% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): Exponent's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 6.75%, the company may face hurdles in achieving optimal financial returns.

Return on Assets (ROA): Exponent's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.69% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: With a below-average debt-to-equity ratio of 0.21, Exponent adopts a prudent financial strategy, indicating a balanced approach to debt management.

To track all earnings releases for Exponent visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
EarningsBZI-EP
EXPO Logo
EXPOExponent Inc
$70.09-%
Overview
  • Analysts currently favor an Buy trajectory for Science Applications Intl, with an average 1-year price target of $123.25, suggesting a potential 76.27% upside.
  • Analysts currently favor an Buy trajectory for Andersen Group, with an average 1-year price target of $29.5, suggesting a potential 57.81% downside.
  • Analysts currently favor an Neutral trajectory for CBIZ, with an average 1-year price target of $60.0, suggesting a potential 14.19% downside.
Company Consensus Revenue Growth Gross Profit Return on Equity
Huron Consulting Gr Buy 16.71% $143.56M 6.24%
Science Applications Intl Buy -5.57% $227M 5.15%
Andersen Group Buy 14.81% $44.77M 36.75%
CBIZ Neutral 58.09% $90.13M 1.60%

Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.

Revenue Growth: Exponent's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 7.95%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.

EXPO Logo
EXPOExponent Inc
$70.09-%
Overview
Comments
Loading...